MIR22HG: A Potential Drug Target Or Biomarker for Cancer (G84981)
MIR22HG: A Potential Drug Target Or Biomarker for Cancer
MIR22HG, also known as MIR22 host gene, transcript variant 1, is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer. MIR22HG is a member of the MIR22 family, which is known for its role in the regulation of microRNA (miRNA) levels. The MIR22 family plays a crucial role in post-transcriptional gene regulation by binding to specific target RNAs and affecting their stability and translation efficiency.
The MIR22HG gene is located on chromosome 19 at position 18.2 kb and encodes a protein named MIR22. MIR22 is a 22-kDa protein that consists of a N-terminal alpha-helix, a middle alpha-helix, and a C-terminal T- loop. The protein has a predicted localization in the cytoplasm and is involved in various cellular processes, including cell adhesion, migration, and invasion.
MIR22HG has been shown to play a crucial role in the regulation of miRNA levels in various organisms, including humans. MIR22HG has been shown to interact with miR18a, a well-known regulator of cell proliferation and survival, to enhance its effects on cell growth and survival. MIR22HG has also been shown to physically interact with miR21, another key regulator of cell growth and development, to regulate the translation efficiency of miR21-containing RNAs.
In addition to its role in regulating miRNA levels, MIR22HG has also been shown to play a crucial role in the regulation of cellular processes that are important for cancer progression. For example, MIR22HG has been shown to promote the growth and survival of various cancer cells. types, including breast, ovarian, and colorectal cancer. MIR22HG has also been shown to contribute to the development of resistance to chemotherapy in cancer cells.
Given the potential role of MIR22HG as a drug target or biomarker, various studies have been undertaken to investigate its potential clinical applications. For example, researchers have used RNA interference (RNAi) technology to knockdown MIR22HG in cancer cells and assess its effects on cell growth and survival. Results have shown that MIR22HG plays a crucial role in the regulation of miRNA levels and that its knockdown has a significant impact on cell behavior.
Another study has used a similar RNAi technology to investigate the effects of MIR22HG on the translation efficiency of miR21-containing RNAs in cancer cells. Results have shown that MIR22HG has a positive impact on the translation efficiency of miR21-containing RNAs and that its increase in can enhance the effects of miR21.
In addition to these studies, researchers have also used live cell imaging techniques to investigate the localization and stability of MIR22HG in cancer cells. Results have shown that MIR22HG is predominantly located in the cytoplasm and that it is highly stable in the cytoplasm, which suggests that it is involved in the regulation of miRNA levels in the cytoplasm.
Overall, MIR22HG is a gene that has been shown to play a crucial role in the regulation of miRNA levels and has potential as a drug target or biomarker for various diseases, including cancer. Further studies are needed to fully understand the role of MIR22HG in cellular processes and its potential clinical applications.
Protein Name: MIR22 Host Gene
The "MIR22HG Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR22HG comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MIR2355 | MIR2392 | MIR23A | MIR23AHG | MIR23B | MIR23C | MIR24-1 | MIR24-2 | MIR2467 | MIR25 | MIR2681 | MIR2682 | MIR26A1 | MIR26A2 | MIR26B | MIR27A | MIR27B | MIR28 | MIR2861 | MIR2909 | MIR296 | MIR297 | MIR298 | MIR299 | MIR29A | MIR29B1 | MIR29B2 | MIR29B2CHG | MIR29C | MIR300 | MIR301A | MIR301B | MIR302A | MIR302B | MIR302C | MIR302D | MIR302E | MIR302F | MIR3059 | MIR3064 | MIR3065 | MIR3074 | MIR3085 | MIR30A | MIR30B | MIR30C1 | MIR30C2 | MIR30D | MIR30E | MIR31 | MIR3115 | MIR3116-1 | MIR3116-2 | MIR3117 | MIR3118-1 | MIR3118-2 | MIR3118-3 | MIR3118-4 | MIR3118-5 | MIR3118-6 | MIR3119-1 | MIR3119-2 | MIR3120 | MIR3121 | MIR3122 | MIR3123 | MIR3124 | MIR3125 | MIR3126 | MIR3127 | MIR3128 | MIR3129 | MIR3130-1 | MIR3130-2 | MIR3131 | MIR3132 | MIR3133 | MIR3134 | MIR3135A | MIR3135B | MIR3136 | MIR3137 | MIR3138 | MIR3139 | MIR3140 | MIR3141 | MIR3142 | MIR3142HG | MIR3143 | MIR3144 | MIR3145 | MIR3146 | MIR3147 | MIR3147HG | MIR3148 | MIR3149 | MIR3150A | MIR3150B | MIR3151 | MIR3152
